Capua BioServices, mRNA and Biologics Facility
DPS is executing a feasibility study for Capua BioServices for a manufacturing area that will allow them to enter in to the CDMO market for microbial parenteral biologic substances and mRNA vaccines production.
About this project
To support business expansion, Capua BioServices is evaluating a new manufacturing area that will allow them to enter in to the CDMO market for microbial parenteral biologic substances and mRNA vaccines production.
DPS is reviewing several options to create a new production facility in the existing Capua BioServices facility in Italy. The feasibility study will generate a report with high-level cost estimate, optional floorplans, equipment list and a project schedule.
The feasibility study will offer two layouts for both a mRNA and microbial parenteral biologic substances production facility (accompanied by an Equipment List).
The feasibility report and floorplans will address:
- cGMP compliance
- Personnel & Materials flows
- Process operability
- Area Classification
The layouts and equipment list are the foundation for the development of the high-level CAPEX Cost Estimate and Project Timeline for the brownfield (800 m2) and the greenfield (1500 m2) scenario.
The TIC (Total Installed Cost) from the cost estimate will be used to derive the engineering fees for the Concept phase, Basic Engineering phase, EPCC (Detail Engineering, Procurement, Construction & Commissioning) and Qualification.
Tell us about your project
and discover how DPS can help you today